17 April 2017
Abgentis' Lead programme demonstrates efficacy against multi-drug resistant Gram-negatives
GYR12, Abgentis' lead novobiocin analogue, in combination with colistin, is effective against colistin-resistant strains of E. coli, K. pneumoniae and A. baumannii. Sub-microgramme per ml concentrations of GYR12 with 2 ug/ml of colistin kill strains that are resistant to either compound alone. Colistin-resistant (MIC >256 ug/ml colistin) can be fully resensitised and killed.
The GYR12/colistin combination provides a broad-spectrum opportunity which Abgentisis evaluating through detailed preclinical studies.